Search results for " arthritis"

showing 10 items of 629 documents

Antiphospholipid syndrome in obstetrics.

2003

Antiphospholipid syndrome (APLS) in pregnancy is characterized by the presence of autoantibodies in association with recurrent fetal loss and severe complications such as preeclampsia, fetal growth retardation, or placental insufficiency. The most clinically important serologic markers are lupus anticoagulant, anticardiolipin antibodies, and recently anti-beta-2-glycoprotein 1 antibodies. At present, standardization does not exist and a definitive association between specific clinical manifestation and antibody level is not yet known. Experimental data gave evidence that passive transfer of antiphospholipid antibodies result in clinical manifestation of APLS, that is, fetal loss and thromb…

Adultmedicine.medical_specialtyAbortion HabitualPlacental insufficiency030204 cardiovascular system & hematologyGastroenterologyPreeclampsia03 medical and health sciences0302 clinical medicinePre-Eclampsiaimmune system diseasesAntiphospholipid syndromePregnancyInternal medicinemedicinePrevalenceHumansThrombophiliaAnnexin A5030203 arthritis & rheumatologyLupus anticoagulantAspirinPregnancyFetal Growth RetardationAspirinbusiness.industryHeparinStandard treatmentInfant NewbornAnticoagulantsImmunoglobulins IntravenousHematologyGeneral MedicineHeparinmedicine.diseaseAntiphospholipid SyndromePlacental InsufficiencyThrombocytopeniaAbortion SpontaneousPregnancy ComplicationsAntibodies AnticardiolipinLupus Coagulation InhibitorImmunologyPrednisoneFemalebusinessImmunity Maternally-AcquiredImmunosuppressive Agentsmedicine.drugClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
researchProduct

Women’s Foot Health–Related Quality of Life in Ballet Dancers and Nondancers

2020

Background: Prevalence and severity of symptoms related to muscle and joint pain seem to be high in most dancers. Hypothesis: There will be a worse quality of life related to foot health for ballet dancers compared with nondancers. Study Design: Case-control study. Level of Evidence: Level 4. Methods: A sample of 156 women was recruited from a clinic of podiatric medicine and surgery. Self-reported data were measured by the Foot Health Status Questionnaire (FHSQ), which has 33 questions that assess 8 health domains of the feet and general health, namely, foot pain, foot function, general foot health, footwear, general health, physical activity, social capacity, and vigor. Results: Statistic…

Adultmedicine.medical_specialtyAdolescentDanceBalletCalidad de vidaHealth StatusPhysical Therapy Sports Therapy and RehabilitationYoung Adult03 medical and health sciences0302 clinical medicineQuality of life (healthcare)PrevalencemedicineHumansOrthopedics and Sports MedicineDancingFoot disease030203 arthritis & rheumatologyHealth related quality of lifeFootbusiness.industryMyalgia030229 sport sciencesDeporteMiddle AgedArthralgiaEfectos fisiológicosDanzaFisiología del ejercicioCase-Control StudiesFocus Topic: Sex-Based DifferencesJoint painQuality of LifePhysical therapyFemalemedicine.symptomBallet dancerbusinessFoot (unit)Sports Health: A Multidisciplinary Approach
researchProduct

Treatment of cutaneous lupus erythematosus: current practice variations

2015

The treatment of cutaneous lupus erythematous (CLE) remains a challenge. Most of the therapeutic options used in CLE have not been tested in randomized controlled studies and to date no agent has been approved. Therefore, CLE treatment is mostly based on personal experience. To better characterize therapeutic habits among physicians treating CLE patients, a questionnaire-based study about various aspects of topical and systemic treatment for CLE has been performed. The questionnaire was distributed among CLE experts, mostly from Japan, the USA, and Europe. A total of 82 completed questionnaires were assessed. High-potent and potent corticosteroids as well as calcineurin inhibitors were the…

Adultmedicine.medical_specialtyCalcineurin InhibitorsDiseaseControlled studiesSystemic therapyAntimalarials030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineJapanRheumatologyAdrenal Cortex HormonesSurveys and QuestionnairesLupus Erythematosus CutaneousmedicineHumansPractice Patterns Physicians'Aged030203 arthritis & rheumatologybusiness.industryfungiTreatment optionsMiddle AgedDermatologyUnited StatesEuropeCalcineurinTreatment OutcomeCurrent practiceConcomitantImmunologyCutaneous Lupus ErythematosusbusinessLupus
researchProduct

Aortic root dilation in associated with the reduction in capillary density observed at nailfold capillaroscopy in SSc patients

2020

Systemic sclerosis (SSc) is an autoimmune disease characterized by endothelial dysfunction and fibroblasts activation. Microvascular disease may be easily observed by means of nailfold capillaroscopy. Recent evidences emphasized also the involvement of large-medium arteries in SSc, mainly in terms of increased stiffness of the vessel wall. The study aims to measure aortic root diameter in a cohort of SSc patients and to correlate echocardiographic findings with the capillaroscopic pictures. We analyzed the clinical records of 125 consecutive SSc patients (M/F 14/111, mean age 55 ± 12.7 years, median disease duration 11 years) referring in 3 second-level rheumatology centers. All subjects un…

Adultmedicine.medical_specialtyVasa vasorumMicroscopic Angioscopy03 medical and health sciences0302 clinical medicineRheumatologyInternal medicineMedicineAortic rootHumans030212 general & internal medicineEndothelial dysfunctionNailfold CapillaroscopyVideocapillaroscopyAged030203 arthritis & rheumatologyAutoimmune diseaseScleroderma Systemicintegumentary systembusiness.industryMicroangiopathyGeneral MedicineMiddle Agedmedicine.diseaseDilatationRheumatologyCapillariesmedicine.anatomical_structureCapillary densityNailsVasa vasorumCardiologySystemic sclerosisbusinessAortic root dilation
researchProduct

Hyaluronic acid and platelet-rich plasma, a new therapeutic alternative for scleroderma patients: a prospective open-label study

2019

Abstract Background Systemic sclerosis is a systemic connective tissue disease characterized by endothelium damage, fibrosis, and subsequent atrophy of the skin. Perioral fibrosis produces a characteristic microstomia together with microcheilia, both of which cause severe difficulties and affects patients’ daily life, such as eating and oral hygiene. Since there are no effective and specific therapies, we have aimed at evaluating the response to filler injections of hyaluronic acid together with platelet-rich plasma. Methods Ten female patients aged between 18 and 70 were included in this study. Each patient was treated with three filler injections of hyaluronic acid and platelet-rich plasm…

Adultmedicine.medical_specialtylcsh:Diseases of the musculoskeletal systemHyaluronic acidMicrocheiliaGastroenterologySystemic sclerosi030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAtrophyPlatelet-rich plasmaFibrosisInternal medicineHyaluronic acidmedicineHumansProspective StudiesHyaluronic acid; Platelet-rich plasma; Systemic sclerosis; TherapySkin030203 arthritis & rheumatologyScleroderma SystemicViscosupplementsMicrostomiabusiness.industryMiddle Agedmedicine.diseaseConnective tissue diseaseElasticityLipRheumatologySettore MED/16 - ReumatologiaTreatment OutcomechemistryPlatelet-rich plasmaQuality of LifeSystemic sclerosisFemaleTherapylcsh:RC925-935businessResearch ArticleArthritis Research & Therapy
researchProduct

Editorial: Clinical Trials in Raynaud's Phenomenon: A Spoonful of Sugar (Pill) Makes the Medicine Go Down (in Flames)

2017

Objective To determine the effect of selexipag, an oral, selective IP prostacyclin receptor agonist, on the frequency of attacks of Raynaud's phenomenon (RP) in patients with systemic sclerosis (SSc). Methods Patients with SSc‐related RP were randomized 1:1 to placebo (n = 38) or selexipag (n = 36) in individualized doses (maximum of 1,600 μg twice daily) during a 3‐week titration period. The primary end point was the weekly average number of RP attacks during the study maintenance period, analyzed using a Bayesian approach with a negative binomial model adjusted for baseline number of RP attacks. Other outcome measures included Raynaud's Condition Score (RCS), RP attack duration, and treat…

Adultmedicine.medical_specialtymedicine.drug_classImmunologyIschemiaSystemic SclerosisCalcium channel blockerScleroderma03 medical and health sciences0302 clinical medicineRheumatologyAcetamidesmedicineHumansImmunology and Allergy030212 general & internal medicineskin and connective tissue diseasesIntensive care medicine030203 arthritis & rheumatologyScleroderma Systemicintegumentary systembusiness.industryVascular diseaseRaynaud DiseaseVasospasmmedicine.diseaseSurgeryClinical trialPyrazinesPillOriginal ArticleSugarsbusinessVasodilating AgentArthritis & Rheumatology
researchProduct

2021 revised algorithm for the management of knee osteoarthritis-the Chinese viewpoint.

2021

Abstract Aim The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) algorithm for the management of knee osteoarthritis (OA) is available worldwide from 2014, but in 2019 an update was published. Based on this algorithm, a Working Group (WG), including ESCEO members and Chinese experts, wished to see how the new ESCEO algorithm was perceived by Chinese experts in knee OA and how it was integrated into their clinical practice. Methods A WG was held between members of the international ESCEO task force and a group of Chinese experts. Results Non-pharmacological approach should be combined with pharmacological interventions. …

AgingChinaSymptomatic slow-acting drugs for osteoarthritisOsteoarthritis03 medical and health sciences0302 clinical medicineMedicineHumans030212 general & internal medicineKnee osteoartrhitis · Patented crystalline glucosamine sulfate · Symptomatic slow-acting drugs for osteoarthritis · Algorithm · ChinaConsensus Document030203 arthritis & rheumatologyGlucosamineKnee osteoartrhitisbusiness.industryGeriatrics gerontologyTask forceAnti-Inflammatory Agents Non-SteroidalChondroitin SulfatesPatented crystalline glucosamine sulfateOsteoarthritis Kneemedicine.diseaseClinical PracticeAlgorithmPharmacological interventionsGeriatrics and GerontologybusinessAlgorithmAlgorithmsAging clinical and experimental research
researchProduct

2019 revised algorithm for the management of knee osteoarthritis: the Southeast Asian viewpoint

2021

Abstract Background Since 2014, the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) algorithm for the management of knee osteoarthritis (OA) is available worldwide. Aim Based on this document, a Southeast Asia Working Group (SEAWG) wished to see how the new ESCEO algorithm developed in 2019 was perceived by Southeast Asian experts and how it was integrated into their clinical practice. Methods A SEAWG was set up between members of the international ESCEO task force and a group of Southeast Asian experts. Results Non-pharmacological management should always be combined with pharmacological management. In step 1, symptoma…

AgingSymptomatic slow-acting drugs for osteoarthritisPharmacological managementOsteoarthritisSoutheast asianSoutheast asia03 medical and health sciences0302 clinical medicineMedicine and Health SciencesHumansMedicine030212 general & internal medicineLimited evidenceConsensus DocumentReimbursement030203 arthritis & rheumatologyGlucosamineKnee osteoartrhitisbusiness.industryTask forceAnti-Inflammatory Agents Non-SteroidalChondroitin SulfatesPatented crystalline glucosamine sulfateOsteoarthritis KneeKnee osteoartrhitis · Patented crystalline glucosamine sulfate · Symptomatic slow-acting drugs for osteoarthritis · Algorithmmedicine.diseaseAlgorithmClinical PracticeGeriatrics and GerontologybusinessAlgorithmAlgorithms
researchProduct

Chronic gout in the elderly

2013

Gout is the most common cause of inflammatory arthritis in men over 40 years old; it is a debilitating disease and, if untreated, can result in a chronic progressive disease, including tophaceous gout. In the elderly it represents a special issue, with notable clinical and therapeutic differences from the classical form with a systemic involvement. The burden of the disease increases particularly in the very old people, in whom arthritis, impaired gait and eyesight problems may enhance the related disability. Chronic gout moreover could aggravate heart and kidney disease and increase overall mortality and organ-related damage. Early diagnosis and appropriate treatment are important goals fo…

Agingmedicine.medical_specialtyGoutInflammatory arthritisArthritisDiseaseHyperuricemiaGout SuppressantsChronic gout Hyperuricemia Tophi Older ageRisk FactorsEpidemiologymedicineHumansHyperuricemiaIntensive care medicineLife StyleAgedbusiness.industrymedicine.diseaseGoutChronic DiseasePhysical therapyGeriatrics and GerontologybusinessProgressive diseaseKidney disease
researchProduct

Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real life clinical practice: a nationwide multicenter retrospective observ…

2018

A few studies have reported the safety profile of interleukin (IL)-1 blockers from real life. The aim of this study is to describe anakinra (ANA) and canakinumab (CAN) safety profile in children and adults, based on data from a real-life setting. Demographic, clinical, and therapeutic data from patients treated with ANA and CAN were retrospectively collected and analyzed. Four hundred and seventy five patients were enrolled; ANA and CAN were prescribed in 421 and 105 treatment courses, respectively. During a mean follow-up of 24.39 ± 27.04 months, 89 adverse events (AE) were recorded; 13 (14.61%) were classified as serious AE (sAE). The overall estimated rate of AE and sAE was 8.4 per 100 p…

Anakinra; Autoinflammatory disorders; Canakinumab; Interleukin-1; Safety profile0301 basic medicineMaleSettore MED/16 - REUMATOLOGIAAutoinflammatory disorders0302 clinical medicineRetrospective StudieAnakinra; Autoinflammatory disorders; Canakinumab; Interleukin-1; Safety profile; RheumatologyChildAntibodies MonoclonalGeneral MedicineMiddle AgedAnakinraTreatment OutcomeAutoinflammationFemaleCohort studymedicine.drugHumanAdultmedicine.medical_specialtyAdolescentLogistic ModelCanakinumabNeutropeniaAntibodies Monoclonal HumanizedAutoimmune DiseaseAutoimmune Diseases03 medical and health sciencesYoung AdultRheumatologyInternal medicineInjection site reactionmedicineHumansAnakinra Autoinflammatory disorders Canakinumab Interleukin-1 Safety profile Adolescent Adult Antibodies Monoclonal Antibodies Monoclonal Humanized Autoimmune Diseases Child Female Humans Interleukin 1 Receptor Antagonist Protein Logistic Models Male Middle Aged Retrospective Studies Treatment Outcome Young AdultAdverse effectRetrospective Studies030203 arthritis & rheumatologyAnakinrabusiness.industryRetrospective cohort studymedicine.diseaseCanakinumabInterleukin 1 Receptor Antagonist ProteinLogistic Models030104 developmental biologyAutoinflammatory disorderSafety profileObservational studybusinessInterleukin-1
researchProduct